Search research articles
Contact Us
Filters
Showing results (31-40 of 70) with videos related to
Page
of 7
Sort By:
Biochimica Et Biophysica Acta
|
December 3, 2014
Targeting protein kinase C in sarcoma
J Martin-Liberal, A J Cameron, J Claus, et al.
Biochemical Pharmacology
|
December 14, 1993
The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice
D I Jodrell, W Gibson, G M Bisset, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation
C J Rutty, I R Judson, G Abel, et al.
Biochemical Pharmacology
|
February 24, 1993
The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells
W Gibson, G M Bisset, P R Marsham, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 29, 2000
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
H M Coley, M W Verrill, S E Gregson, et al.
Biochemical Pharmacology
|
May 11, 1995
The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies
H M Coley, N Brooks, D H Phillips, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 20, 2003
Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics
P M J McSheehy, H Troy, L R Kelland, et al.
Journal of Inorganic Biochemistry
|
January 8, 2000
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
L R Kelland, S Y Sharp, C F O'Neill, et al.
British Journal of Cancer
|
February 1, 1991
Phase II trial of trimelamol in refractory ovarian cancer
I R Judson, A H Calvert, M E Gore, et al.
Journal of Medicinal Chemistry
|
December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl
M Jarman, H M Coley, I R Judson, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 70) with videos related to
Sort By:
Page
of 7
Biochimica Et Biophysica Acta
|
December 3, 2014
Targeting protein kinase C in sarcoma
J Martin-Liberal, A J Cameron, J Claus, et al.
Biochemical Pharmacology
|
December 14, 1993
The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice
D I Jodrell, W Gibson, G M Bisset, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation
C J Rutty, I R Judson, G Abel, et al.
Biochemical Pharmacology
|
February 24, 1993
The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells
W Gibson, G M Bisset, P R Marsham, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 29, 2000
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
H M Coley, M W Verrill, S E Gregson, et al.
Biochemical Pharmacology
|
May 11, 1995
The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies
H M Coley, N Brooks, D H Phillips, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 20, 2003
Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics
P M J McSheehy, H Troy, L R Kelland, et al.
Journal of Inorganic Biochemistry
|
January 8, 2000
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
L R Kelland, S Y Sharp, C F O'Neill, et al.
British Journal of Cancer
|
February 1, 1991
Phase II trial of trimelamol in refractory ovarian cancer
I R Judson, A H Calvert, M E Gore, et al.
Journal of Medicinal Chemistry
|
December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl
M Jarman, H M Coley, I R Judson, et al.
Page
of 7